Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sulfuric Acid SCHEMBL31172741 | 1.00 | — | — | |
| Sulfuric Acid SCHEMBL137840 | 1.00 | MEN1 (0.39) | MEN1ALDH1A1TSHRKMT2ATP53 | |
| Sulfuric Acid SCHEMBL2031104 | 1.00 | MEN1 (0.39) | MEN1ALDH1A1TSHRKMT2ATP53 | |
| Sulfuric Acid SCHEMBL8580664 | 1.00 | MEN1 (0.39) | MEN1ALDH1A1TSHRKMT2ATP53 | |
| Sulfuric Acid SCHEMBL736943 | 0.94 | MEN1 (0.42) | MEN1ALDH1A1TSHRKMT2ATP53 | |
| Sulfuric Acid SCHEMBL5466599 | 0.94 | MEN1 (0.42) | MEN1ALDH1A1TSHRKMT2ATP53 | |
| Sulfuric Acid SCHEMBL65507 | 0.94 | MEN1 (0.42) | MEN1ALDH1A1TSHRKMT2ATP53 | |
| Sulfuric Acid SCHEMBL49535 | 0.94 | — | — | |
| Sulfuric Acid SCHEMBL21059468 | 0.94 | MEN1 (0.42) | MEN1ALDH1A1TSHRKMT2ATP53 | |
| Sulfuric Acid SCHEMBL905465 | 0.94 | MEN1 (0.42) | MEN1ALDH1A1TSHRKMT2ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090071618-A1 | HIGH-PERFORMANCE STRENGTH RESINS IN PAPERMAKING INDUSTRIES | KEMIRA OYJ (FI) | 2009-03-19 | — | — | US | claimed |
| EP-1828479-A1 | HIGH-PERFORMANCE STRENGTH RESINS IN PAPERMAKING INDUSTRIES | Lanxess Corporation (US) | 2007-09-05 | — | — | EP | claimed |
| WO-2006016906-A1 | HIGH-PERFORMANCE STRENGTH RESINS IN PAPERMAKING INDUSTRIES | LANXESS CORPORATION (US) | 2006-02-16 | — | — | WO | claimed |
| US-20010047034-A1 | Inhibiting oxidative degradation of pharmaceutical formulations | WANG HAI (US) | 2001-11-29 | — | — | US | claimed |
| EP-1145719-A2 | Use a ferrous salt for inhibiting oxidative degradation of pharmaceutical formulations | Pfizer Products Inc. (US) | 2001-10-17 | — | — | EP | claimed |
| US-3931121-A | METALLIC OR METALLIC SALT ACCELERATOR | BASF WYANDOTTE CORPORATION (US) | 1976-01-06 | — | — | US | claimed |
| CN-115739142-B | H used in semiconductor manufacturing wastewater2O2Preparation method of removed magnetic nano enzyme | 南京大学 | 2024-06-25 | — | — | CN | disclosed |
| CN-115184540-A | On-line mercury automatic analyzer based on titration analysis and analysis method | 福建省吉龙德环保科技有限公司 | 2022-10-14 | — | — | CN | disclosed |
| US-10426751-B2 | Allosteric activators for treatment of phenylketonuria | MCMASTER UNIVERSITY (CA) | 2019-10-01 | — | — | US | disclosed |
| US-20180064672-A1 | ALLOSTERIC ACTIVATORS FOR TREATMENT OF PHENYLKETONURIA | MCMASTER UNIVERSITY (CA) | 2018-03-08 | — | — | US | disclosed |
| EP-3242658-A1 | ALLOSTERIC ACTIVATORS FOR TREATMENT OF PHENYLKETONURIA | Mcmaster University (CA) | 2017-11-15 | — | — | EP | disclosed |
| WO-2016109899-A1 | ALLOSTERIC ACTIVATORS FOR TREATMENT OF PHENYLKETONURIA | MCMASTER UNIVERSITY (CA) | 2016-07-14 | — | — | WO | disclosed |
| US-20090234032-A1 | HYDROPHILIC, COMPOSITE, MICROPOROUS MEMBRANE AND ITS PRODUCTION METHOD | TONEN CHEMICAL CORPORATION (JP) | 2009-09-17 | — | — | US | disclosed |
| EP-1961784-A1 | HYDROPHILIC COMPOSITE MICROPOROUS MEMBRANE AND METHOD FOR PRODUCING SAME | Tonen Chemical Corporation (JP) | 2008-08-27 | — | — | EP | disclosed |
| EP-1184392-B1 | STABILIZED DENATURED LIPOPROTEIN AND PROCESS FOR PRODUCING THE SAME | KYOWA MEDEX CO LTD (JP) | 2007-04-04 | — | — | EP | disclosed |
| EP-1184392-A1 | STABILIZED DENATURED LIPOPROTEIN AND PROCESS FOR PRODUCING THE SAME | Vessel Research Laboratory Co., Ltd. (JP) | 2002-03-06 | — | — | EP | disclosed |
| US-5922563-A | A NUCLEIC ACID MOLECULE; DIAGNOSIS, PREVENTING AND CONTROLLING SEXUALLY TRANSMITTED DISEASES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1999-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010047034-A1 | Inhibiting oxidative degradation of pharmaceutical formulations | SQOR, HMOX1, PRDX3 | MEN1 3779/4885ALDH1A1 350/4885TSHR 3675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.